Prognostic value of miR-17-5p in cancers: a meta-analysis

Figures & data

Figure 1 Study flow chart showing the process for selecting eligible publications.

Table 1 Characteristics of the included studies

Tumor type	Reference	Region	Sample size	Specimen source	Test method	Definition of high miR-17-5p expression	Rate of high miR-17-5p expression	Tumor stage	Follow-up time (months)	Survival	HR
HCC	Chen et al^Citation10	China	120	Tissue	PCR	Median	56.7	Edmondson–Steiner grade (I–IV)	2–46	OS^MA DFS^MA	RR
CIE	Zakrzewska et al^Citation15	Poland	53	Tissue	PCR	Median	NR	WHO (I–III)	Up to 120	OS^MA EFS^MA	R
GC	Wang et al^Citation17	China	65	Plasma	PCR	Median	50.8	TNM (I–IV)	Up to 40	OS^UA	R
CC	Diaz et al^Citation18	Spain	62	Tissue	PCR	Tertile	33.9	TNM (I–IV)	68–99	OS^UA DFS^UA	R
HCC	Zheng et al^Citation11	China	96	Serum	PCR	Median (2.705)	50	TNM (I–IV)	From resection to death or May 1, 2012	OS^MA	R
PC	Yu et al^Citation19	Japan	80	Tissue	PCR	Cutoff value (5.69)	37.5	UICC (I–IV)	Up to 100	OS^MA	R
CRC	Fang et al^Citation13	China	295	Tissue	PCR ISH	Staining score (8–12)	30.2	TNM (I–IV)	Up to 96	OS^MA	R
NPC	Chen et al^Citation16	China	81	Tissue	PCR	Staining score (tai)	75.3	TNM (I–IV)	Up to 100	OS^UA	SC
LC	Chen et al^Citation12	China	221	Serum	PCR	Median (33 months)	45.7	TNM (I–IV)	Up to 50	OS^UA	R
OSA	Zhu et al^Citation14	China	62	Plasma	PCR	Mean	NR	TNM (I–III)	10–70 (OS) 10–60 (PFS)	OS^MA PFS^MA	R

Abbreviations: HR, hazard ratio; HCC, hepatocellular carcinoma; CIE, childhood infratentorial ependymoma; GC, gastric cancer; CC, colon cancer; PC, pancreatic cancer; CRC, colorectal cancer; NPC, nasopharyngeal carcinoma; LC, lung cancer; OSA, osteosarcoma; PCR, polymerase chain reaction; ISH, in situ hybridization; NR, not reported; WHO, World Health Organization; TNM, tumour node metastases; UICC, Union for International Cancer Control; OS, overall survival; PFS, progress-free survival; DFS, disease-free survival; MA, multivariate analysis; UA, univariate analysis; RR, risk ratio; R, reported; SC, survival curve.

Figure 2 Forest plot of the overall survival analysis.

Note: Weights are from random-effects analysis.
Abbreviations: CI, confidence interval; ES, effect size.

Table 2 The pooled HRs, 95% CIs, heterogeneity, and P-values of overall survival stratified by sample size, ethnicity, sample sources, definition method, tumor type, and statistical mode

Stratified analysis	Number of studies	Number of patients	Pooled HR (95% CI)	P-value	Heterogeneity			Test of interaction
					I^2 (%)	p-value	Model	P-value
Sample size								0.49
≥100	3	636	2.15 (1.37–3.37)	0.001	38.6	0.196	Random
<100	7	499	1.72 (1.11–2.68)	0.016	48.6	0.070	Random
Dominant ethnicity								0.82
Asian	8	1,020	1.92 (1.37–2.71)	0.000	47.2	0.066	Random
European	2	115	1.69 (0.57–5.00)	0.344	55.6	0.133	Random
Source								0.48
Tissue	6	691	1.69 (1.05–2.71)	0.031	50.7	0.071	Random
Serum/plasma	4	444	2.13 (1.36–3.31)	0.001	40.5	0.169	Random
Definition								0.80
Median	5	555	2.08 (1.54–2.81)	0.000	1.5	0.398	Random
Stain score	2	376	1.77 (0.57–5.50)	0.327	76.4	0.015	Random
Others	3	204	1.76 (1.15–2.67)	0.008	0	0.438	Random
Tumor types								0.15
Digestive system	6	718	1.73 (1.20–2.49)	0.003	45.2	0.104	Random
Respiratory system	2	302	1.63 (1.02–2.60)	0.040	0	0.531	Random
Others	2	115	5.33 (1.72–16.50)	0.004	27.3	0.241	Random
Statistical mode								0.19
Univariate analysis	4	429	1.59 (1.17–2.17)	0.003	0	0.663	Random
Multivariate analysis	6	706	2.43 (1.39–4.26)	0.002	61.4	0.024	Random

Note: Data in bold P<0.05.

Abbreviations: CI, confidence interval; HR, hazard ratio.

Figure 3 Forest plot of disease free survival analysis.

Abbreviations: CI, confidence interval; ES, effect size.

Table 3 Meta-analysis results of the correlation between elevated miR-17-5p expression and multiple clinicopathological characteristics

Stratified analysis	Number of studies	Number of patients	Pooled OR (95% CI)	P-value	Heterogeneity
					I^Citation2 (%)	P-value	Model
Age (old vs young)	6	663	1.08 (0.95–1.24)	0.240	0	0.578	Fixed
Gender (male vs female)	6	663	0.92 (0.80–1.05)	0.212	0	0.809	Fixed
Invasion depth (T3+T4 vs T1+T2)*	2	160	1.45 (0.61–3.45)	0.400	87.7	0.004	Random
Lymph node invasion (≥2 vs <2)	2	201	1.28 (1.05–1.56)	0.016	0	0.404	Fixed
Distant metastasis (yes vs no)	3	242	1.24 (0.66–2.32)	0.499	83.4	0.002	Random
Tumor stage (III+IV vs I+II)	4	463	1.09 (0.56–2.10)	0.804	88.8	0.000	Random
Venous invasion (yes vs no)	2	200	1.92 (1.40–2.63)	0.000	0	0.776	Fixed
Differentiation grade (poorly vs well and moderately)	2	161	1.33 (0.97–1.84)	0.077	0	0.361	Fixed
Tumor size (>5 vs <5) (cm)	3	281	0.90 (0.62–1.30)	0.291	53.4	0.117	Random
Hepatitis history (yes vs no)	3	216	1.20 (0.66–2.16)	0.550	58.9	0.119	Random

Notes: According to the size of the tumor and/or the extent of the primary tumor are defined as different T stages. Data in bold P<0.05.

Abbreviations: CI, confidence interval; OR, odds ratio.

Figure 4 Sensitivity analysis of overall survival in this meta-analysis.

Figure 5 Begg’s funnel plot with pseudo 95% CI of the publication bias for overall survival.

Abbreviations: lnhr, logarithm of the hazard ratio; SE, standard error.

ChenLJiangMYuanWTangHmiR-17-5p as a novel prognostic marker for hepatocellular carcinomaJ Invest Surg201225315616122583011

 PubMed Web of Science ®Google Scholar

ZakrzewskaMFendlerWZakrzewskiKAltered microRNA expression is associated with tumor grade, molecular background and outcome in childhood infratentorial ependymomaPLoS One2016117e015846427390862

 PubMed Web of Science ®Google Scholar

WangMGuHWangSCirculating miR-17-5p and miR-20a: molecular markers for gastric cancerMol Med Rep2012561514152022406928

 PubMed Web of Science ®Google Scholar

DiazRSilvaJGarciaJMDeregulated expression of miR-106a predicts survival in human colon cancer patientsGenes Chromosomes Cancer200847979480218521848

 PubMed Web of Science ®Google Scholar

ZhengJDongPGaoSWangNYuFHigh expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinomaHepatogastroenterology20136012354955223108086

 PubMedGoogle Scholar

YuJOhuchidaKMizumotoKFujitaHNakataKTanakaMMicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasionCancer Biol Ther201010874875720703102

 PubMed Web of Science ®Google Scholar

FangLLiHWangLMicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expressionOncotarget20145102974298724912422

 PubMedGoogle Scholar

ChenCLuZYangJMiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21Cancer Med20165123489349927774777

 PubMed Web of Science ®Google Scholar

ChenQSiQXiaoSPrognostic significance of serum miR-17-5p in lung cancerMed Oncol201330135323263848

 PubMed Web of Science ®Google Scholar

ZhuHXLiaoQDYinKDa ZhongDWangCGCirculating miR-17-5p as a potential biomarker for diagnosis and prognosis in osteosarcomaInt J Clin Exp Pathol201710334093416

 Web of Science ®Google Scholar

KleemannMBereutherJFischerSInvestigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosisOncotarget2017812187731879127821806

 PubMedGoogle Scholar